Business · 12/09/2007Updated: 10/17/2026 · 1 min read
FDA's Cardiovascular and Renal Drugs Advisory Committee to Review Amendment of Notice Regarding New Drug Application for Vitrakvi
Summary
The FDA's Cardiovascular and Renal Drugs Advisory Committee will review an amendment to a notice related to a new drug application for Vitrakvi, a treatment for non-small cell lung cancer, as part of its ongoing review process.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →